Pharmaceuticals
ETON's Q2 FY2026 revenue nearly doubled while the company swung from a net loss to a substantial net profit on sharply improved margins, though rising current liabilities and steep R&D cuts present questions for sustainability.
Key risk: Sharp decline in R&D spending
R&D expense fell 73.2% to $0.99 million, which boosted current margins but may impair the company's product pipeline and long-term competitiveness if investment remains low.